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Abstract
Human induced pluripotent stem cells (iPSCs) can be divided into a leukemia inhibitory factor (LIF)-dependent naı ¨ve type
and a basic fibroblast growth factor (bFGF)-dependent primed type. Although the former are more undifferentiated than
the latter, they require signal transduction inhibitors and sustained expression of the transgenes used for iPSC production.
We used a transcriptionally enhanced version of OCT4 to establish LIF-dependent human iPSCs without the use of inhibitors
and sustained transgene expression. These cells belong to the primed type of pluripotent stem cell, similar to bFGF-
dependent iPSCs. Thus, the particular cytokine required for iPSC production does not necessarily define stem cell
phenotypes as previously thought. It is likely that the bFGF and LIF signaling pathways converge on unidentified OCT4
target genes. These findings suggest that our LIF-dependent human iPSCs could provide a novel model to investigate the
role of cytokine signaling in cellular reprogramming.
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Introduction
Mouse pluripotent stem cells can be divided into naı ¨ve and
primed pluripotent cells, depending on their level of pluripotency,
patterns of gene expression, and the cytokines required to
maintain an undifferentiated state (self-renewal) [1,2,3,4,5]. Naı ¨ve
pluripotent stem cells, represented by embryonic stem cells (ESCs)
and standard iPSCs, typically require a combination of LIF and
BMP (bone morphogenetic protein) 2 or BMP4 for self-renewal,
whereas primed pluripotent stem cells, such as epiblast stem cells
(EpiSCs) [6,7], require bFGF and transforming growth factor b/
activin A signaling for self-renewal. Naı ¨ve pluripotent stem cells
can form chimeric mice upon injection into a blastocyst. Primed
pluripotent stem cells can form chimeric mice only at a very low
frequency, if at all. Nonetheless, both cell types retain pluripotency
as exhibited by teratoma formation after being injected into
immunocompromized mice. Naı ¨ve pluripotent stem cells specifi-
cally express Rex1 (Zfp42), Stella (Dppa3) and Klf4 and have two
active X chromosomes in female cells. Primed pluripotent stem
cells specifically express Fgf5 and T (Brachyury) and have only one
active X chromosome in female cells. Morphologically, naı ¨ve
pluripotent stem cells form dome-shaped colonies and can be
cloned after single-cell dissociation; however, primed pluripotent
stem cells demonstrate flat colonies and cannot proliferate well
after single-cell dissociation due to apoptosis. It is currently
thought that primed pluripotent stem cells represent a more
differentiated state than naı ¨ve pluripotent stem cells, reflecting the
developmental stage of the source cells from which each cell type is
derived. ESCs are commonly established from the inner cell mass
of blastocysts around 3.5 days post coitum (dpc). EpiSCs are
typically prepared from epiblasts on 5.5–6.5 dpc [6,7], although
EpiSCs were recently established from blastocysts as well [8].
Unlike their mouse counterparts, human ESCs and iPSCs
appear to be primed pluripotent stem cells [1,2,3,4,5]. These cells
require bFGF for self-renewal, display flat colony morphology, and
tend to enter apoptosis upon single-cell dissociation. In addition,
one of two X chromosomes is generally inactive in female human
ESCs and iPSCs, although this may be dependent on culture
conditions [9,10,11,12]. Instead of the commonly used bFGF, LIF
has also been used to maintain self-renewal. LIF-dependent
human ESCs and iPSCs have characteristics of naı ¨ve stem cells;
however, they require for self-renewal chemical inhibitors against
cell signaling pathways and sustained expression of the transgenes
used to establish iPSCs unlike their mouse counterparts
[13,14,15,16]. For instance, LIF-dependent human iPSCs were
established with inhibitors against extracellular signal-regulated
kinase 1/2 (ERK1/2) and glycogen synthase kinase 3 (GSK3) in
addition to constitutive expression of the transgenes OCT4 plus
KLF4,o rKLF2 plus KLF4 [16]. Expression of these transgenes can
be replaced with forskolin, which induces expression of KLF2 and
KLF4. It is unclear if human LIF-dependent iPSCs can be
established and maintained in the absence of these inhibitors.
We recently established a novel strategy to significantly improve
the efficiency of making mouse and human iPSCs by using a fusion
protein, called M3O, between OCT4 and the powerful transacti-
vation domain of the myogenic master transcription factor
MYOD [17,18]. M3O facilitates transcriptional activation by
OCT4 without disrupting target gene specificity. M3Oi n
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39022Figure 1. Expression of pluripotency markers by iPSCs prepared with LIF or bFGF. (A) Immunofluorescence staining of iPSCs prepared
with LIF or bFGF on day 8. Antibodies against NANOG and TRA1-60 were used, and DNA was counterstained with Hoechst 33342. Bar, 100 mm in (A)
and (C). (B) Formation of iPSC colonies that were double-positive for NANOG and TRA1-60 with LIF, bFGF, or no cytokines. Cells (1.7610
4) were
seeded in each well, and iPSC colonies were counted on day 10. Mean + standard deviation (SD) was obtained from three independent experiments.
(C) Immunofluorescence staining of iPSCs prepared with LIF or bFGF on day 8. Antibodies against SSEA4 and NANOG were used. (D) Formation of
iPSC colonies that were double-positive for SSEA4 and NANOG with bFGF, LIF, or no cytokines. Cells were seeded and iPSC colonies counted as
described in (B).
doi:10.1371/journal.pone.0039022.g001
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increased the efficiency of iPSC colony formation by 10- to 50-
fold and halved the time required for iPSC colony formation as
compared with OCT4 and SKM (OSKM). Because of this high
potency, we hypothesized that M3O-SKM might be capable of
establishing human LIF-dependent iPSCs without having to utilize
sustained transgene activation and chemical inhibitors.
Results and Discussion
Adult human dermal fibroblasts were transduced with retrovi-
ruses expressing M3O-SKM or OSKM. Fibroblasts were subcul-
tured onto feeder cells three days later, when addition of bFGF or
LIF was also started. Control culture was prepared without bFGF
and LIF. ESC-like colonies were defined as iPSC colonies when
they were double-positive for the pluripotency markers NANOG
and TRA1-60 (Fig. 1A). In the presence of bFGF, M3O-SKM
induced iPSC colonies over 20 times more efficiently than OSKM
on day 10 as previously reported [17,18] (Fig. 1B). When bFGF
was omitted or replaced with LIF, iPSC colonies were not
observed with OSKM until day 16 at the earliest. However, iPSC
colonies did appear around day 7 when M3O-SKM was used
without either cytokine. Addition of LIF did not increase the
efficiency of iPSC colony formation. When NANOG and SSEA4
were used as makers for iPSC colonies, similar results were
obtained (Fig. 1C and 1D).
We picked up 20–48 iPSC colonies from each culture condition
between day 10 and 12 when colonies were available. These clones
were then expanded on feeder cells in culture with the same
cytokine to compare their efficiency of establishing pluripotent cell
lines in the absence of signaling inhibitors. More than 90% of
iPSC clones prepared with M3O-SKM in the presence of bFGF
(F-iPSCs) remained undifferentiated for 120 days (25–30 passages)
as monitored by the expression of TRA1-60 and NANOG. In the
absence of bFGF and LIF, however, all iPSC colonies prepared
with M3O-SKM morphologically differentiated by day 15 when
the transgenes were suppressed although they remained undiffer-
entiated if bFGF was added from day 15 onwards. In addition,
most of the iPSC colonies prepared with M3O-SKM in the
presence of LIF (L-iPSCs) differentiated around the same time.
However, a few L-iPSC clones retained morphologically undiffer-
entiated colonies scattered among numerous differentiated colo-
nies beyond day 15. These apparently undifferentiated colonies
were also unstable, with central undifferentiated parts being
surrounded by differentiated derivatives (Fig. 2A). The undiffer-
entiated state of the central parts was verified by the expression of
NANOG and SSEA4 (Fig. 2B). The undifferentiated parts could
be manually picked up during each subculture and expanded
without substantial contamination with differentiated cells until
day 200 at least.
L-iPSCs established with this procedure were characterized with
several approaches. First, suppression of the M3O-SKM trans-
genes was verified by comparing the levels of total mRNA (derived
from endogenous genes and transgenes) encoding OCT4, SOX2,
KLF4 and c-MYC and those derived from endogenous genes. This
was done using PCR primers specific to a 39end untranslated
region and coding region of each gene. Quantitative RT-PCR
indicated that the relative expression levels of the four genes fell
within a 2-fold range as compared with the levels in ESCs for both
total and endogenous genes, suggesting suppression of the
transgenes (Fig. 2C). Similar results were obtained with F-iPSCs.
Suppression of the M3O transgene was also confirmed using a
primer pair that spans the border between the M3 domain and
OCT4 (Fig. 2D).
To rule out the possibility that autocrine bFGF was compen-
sating for the lack of exogenous bFGF in L-iPSC culture, we
blocked the FGF receptor with SU5402, an inhibitor of the FGF
receptor tyrosine kinase [19] between day 8 and 10. The
effectiveness of this treatment was verified by the observation that
the number of F-iPSC colonies decreased to less than 40% of the
control culture treated with the solvent dimethyl sulfoxide for both
OSKM and M3O-SKM (Fig. 2E). However, SU5402 had no
effect on the number of L-iPSC colonies, suggesting that bFGF did
not play a predominant role in the formation of L-iPSC colonies.
In addition, L-iPSCs cultured for 120 days expressed the
pluripotency markers OCT4, NANOG, TRA1-60, TRA1-81
and alkaline phosphatase (Fig. 3A). Expression levels for seven
additional genes enriched in pluripotent cells were similar to those
in ESCs as shown by quantitative RT-PCR (Fig. 3B). Karyotype
was normal in L-iPSCs (Fig. 3C). L-iPSCs also formed teratomas
containing differentiated tissues derived from all three germ layers
following injection into immunocompromized mice, proving
pluripotency of these cells (Fig. 3D). L-iPSCs required the
continuous presence of LIF for self-renewal and could not form
ESC-like colonies after subculture without LIF.
To understand whether L-iPSCs belonged to the naı ¨ve or
primed type, we compared them with F-iPSCs, which are primed
pluripotent stem cells. First, L-iPSC colonies were flat and
morphologically indistinguishable from F-iPSC colonies. Second,
L-iPSCs did not form colonies after single-cell dissociation with
trypsin during subculture, similar to F-iPSCs. Third, F-iPSCs and
L-iPSCs expressed REX1 (ZFP42), STELLA (DPPA3), FGF5 and T
at similar levels (Fig. 4A). Although FGF5 is known to be expressed
in primed pluripotent stem cells as described above, its expression
level was much lower than that in fibroblasts. Fourth, the status of
X chromosome inactivation was investigated by staining L-iPSCs
with an antibody against trimethylation of lysine 27 on histone H3
(H3K27me3), whose enrichment is commonly observed in inactive
X chromosome. Generally, only one X chromosome is active in
female human F-iPSCs [9]. Almost all L-iPSCs showed one
H3K27me3-positive area in each nucleus similar to the original
fibroblasts, suggesting that one of the X chromosomes was
inactivated in L-iPSCs (Fig. 4B). On the basis of the high
similarity between F-iPSCs and L-iPSCs, we concluded that L-
iPSCs belonged to the primed type pluripotent stem cell.
The similarity between F-iPSCs and L-iPSCs was further tested
by examining if LIF in the culture medium of L-iPSCs could be
replaced with bFGF on day 90 without disrupting self-renewal.
After culture for an additional 50 days, the colonies, now called
LF-iPSCs, maintained an ESC-like morphology and expressed
OCT4, NANOG, TRA1-60, TRA1-81 and alkaline phosphatase
(Fig. 5A). This cytokine switch diminished the tendency for
differentiation; LF-iPSC colonies could be maintained in an
undifferentiated state more easily than L-iPSCs. LF-iPSCs also
preserved pluripotency as shown by teratoma formation following
injection into immunocompromized mice (Fig. 5B). In an opposite
experiment, bFGF was replaced with LIF for F-iPSCs, but the cells
did not form any ESC-like colonies after subculture. Thus, unlike
F-iPSCs, the pluripotency of L-iPSCs could be sustained by both
the LIF and bFGF signaling pathways.
Finally, genome-wide transcription patterns were compared
among ESCs, F-iPSCs, L-iPSCs, LF-iPSCs and parent fibroblasts
with a microarray analysis. Overall gene expression patterns were
quite similar among ESCs, two F-iPSC clones, two L-iPSC clones
and two LF-iPSC clones (Fig. 6A). Hierarchical cluster analysis of
genome-wide expression profiles demonstrated that L-iPSCs, F-
iPSCs, LF-iPSCs and ESCs were very closely clustered (Fig. 6B).
mRNAs encoding OCT4, SOX2, NANOG, KLF4, REX1, STELLA,
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39022Figure 2. Characterization of colony morphology, gene expression patterns, and sensitivity to an FGF receptor inhibitor in L-iPSCs
obtained with M3O-SKM. (A) Phase contrast images of L-iPSC colonies obtained on day 90. Bar, 100 mm. (B) Immunofluorescence staining of an L-
iPSC colony with antibodies against NANOG and SSEA4 on day 28. Bar, 100 mm. (C) Quantitative RT-PCR analysis of the OCT4, SOX2, KLF4 and c-MYC
genes in various pluripotent stem cells on day 120. Expression levels of each gene were normalized to GAPDH. The normalized value for ESCs was
defined as 1.0. Mean + SD obtained from three independent experiments are shown. (D) RT-PCR analysis of the expression of M3O in day-3 fibroblasts
transduced with M3O-SKM, day-120 L-iPSCs, and parent fibroblasts. Expression of GAPDH mRNA was monitored as a control. Bar, 100 mm. (E) Effects
of SU5402 on iPSC colony formation with LIF and bFGF. SU5402 dissolved in dimethyl sulfoxide (DMSO) was added to culture medium between day 8
and 10, and the colonies were counted on day 12. DMSO was used as a control.
doi:10.1371/journal.pone.0039022.g002
Figure 3. Characterization of gene expression patterns, karyotype, and teratoma formation in L-iPSCs prepared with M3O-SKM. (A)
Immunofluorescence staining of L-iPSCs with antibodies against OCT4, NANOG, TRA1-60 and TRA1-81 on day 120. Alkaline phosphatase staining is
also shown. Bar, 100 mm. (B) Quantitative RT-PCR analysis of genes that are typically expressed in pluripotent stem cells. Expression levels of each
gene were normalized to GAPDH. The normalized value for ESCs was defined as 1.0. Mean + SD obtained from three independent experiments are
shown. (C) Karyotype analysis of an L-iPSC on day 120. (D) Haematoxylin and eosin staining of histological sections of teratomas derived from L-iPSCs.
Bar, 200 mm.
doi:10.1371/journal.pone.0039022.g003
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pluripotent stem cells, with any differences being less than 1.5-fold
(Fig. 6C).
Our study established L-iPSCs in the absence of sustained
overexpression of transgenes and signaling inhibitors, unlike
previously reported methods of making LIF-dependent human
iPSCs. This was possible because of the usage of the transcrip-
tionally augmented M3O. Reflecting differences in methods, L-
iPSCs were also phenotypically different from previously reported
LIF-dependent iPSCs and more closely related to standard bFGF-
dependent iPSCs. This result has three important implications for
our understanding of the regulation of pluripotency and self-
renewal in iPSCs. First, dependency on LIF or bFGF is not the
primary determinant of naı ¨ve or primed pluripotency. The activity
of transgenes and modulations to cytokine signaling systems
appear to be more critical in determining the type of pluripotent
stem cell. Second, human and mouse cells are fundamentally
different in terms of their response to LIF because this cytokine
induces different types of pluripotent stem cells: primed-type
human iPSCs and naı ¨ve-type mouse iPSCs [18]. Third, this study
suggests that the diverse signaling pathways of LIF and bFGF are
potentially converged at the level of OCT4-target genes. LIF
regulates its target genes primarily through activation of the JAK
kinase and resulting phosphorylation and DNA binding of STAT3
[3]. The main signaling pathway for bFGF is activation of MEK/
ERK, leading to DNA binding of a variety of transcription factors
[20]. There are no well-established overlapping target genes
between these two signaling systems. In future studies, a detailed
comparison of the target genes of OCT4 and M3O could




All animal experiments were approved by the Institutional
Animal Care and Use Committee at the University of Minnesota
(1002A78174).
Figure 4. Characterization of L-iPSCs by using gene expression analyses and immunofluorescence staining of H3K27me3. (A)
Quantitative RT-PCR analysis of genes that are typically expressed in mouse naı ¨ve (REX1 and STELLA) or primed (FGF5 and T) pluripotent stem cells.
Expression levels of each gene were normalized to GAPDH. The normalized value for ESCs was defined as 1.0. Mean + SD obtained from three
independent experiments are shown. (B) Immunofluorescence staining of H3K27me3 as an indicator for X chromosome inactivation. Parent
fibroblasts were stained as a positive control. Nuclei surrounded by squares were magnified (left panels). Arrows indicate H3K27me-positive areas,
corresponding to inactive X chromosomes. Bar, 50 mm.
doi:10.1371/journal.pone.0039022.g004
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39022Figure 5. Characterization of LF-iPSCs with immunofluorescence staining and a teratoma formation assay. (A) Immunofluorescence
staining and alkaline phosphatase staining of LF-iPSCs on day 140. Bar, 100 mm. (B) Haematoxylin and eosin staining of histological sections of
teratomas derived from LF-iPSCs. Bar, 200 mm.
doi:10.1371/journal.pone.0039022.g005
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Human M3O, OCT4, SOX2, KLF4 and c-MYC genes inserted in
the pMXs-IP vector (Addgene) were individually transfected into
Plat-A cells (Cell Biolabs) with Lipofectamin 2000 (Life Technol-
ogies) on day -3. On day -2, 2.7610
4 abdominal skin fibroblasts
isolated from a 34-year-old female (Cell Applications) were plated
in a well of a 12-well plate in DMEM with 10% FBS. On day -1
and day 0, virus supernatant was harvested from Plat-A cells and
transduced each day into fibroblasts with polybrene after filtration
through a 0.45 mm syringe filter. On day 3, transduced cells were
subcultured at 1.7610
4 cells/well onto irradiated mouse embry-
onic fibroblasts on 12-well plates. The culture medium contained
KnockOut DMEM/F-12, 20% KnockOut Serum Replacement,
1% insulin-transferrin-selenium, 1x GlutaMAX (all from Life
Technologies), 100 mM MEM non-essential amino acids, 0.1 mM
2-mercaptoethanol, and either 4 ng/ml bFGF or 1,000 u/ml LIF.
Culture medium was changed every two days. SU5402 (EMD
Biosciences) dissolved in dimethyl sulfoxide (DMSO) was added at
5 mM into the culture medium between day 8 and 10. The human
ESC line WA09 (WiCell) was cultured with 4 ng/ml bFGF in the
culture medium used for iPSCs described above.
Immunofluorescence Staining and Alkaline Phosphatase
Staining
Following fixation with 4% formaldehyde in phosphate-buffered
saline for 10 min, iPSCs were treated with 0.5% Triton X-100 for
3 min to permeabilize the plasma membrane. Primary and
secondary antibodies (Table S1) were applied for 1 hour each at
25uC, followed by DNA counterstain with Hoechst 33342. An
AxioCam charge coupled device camera was used to capture
fluorescence images on an Axiovert 200 M fluorescence micro-
scope (all from Carl Zeiss) equipped with a 10x A-Plan Ph1 Var1
objective (numerical aperture 0.25). Photoshop 7.0 (Adobe
Systems) was used to process images. A Millipore kit (SCR004)
was used for alkaline phosphatase staining following the manu-
facturer’s instructions.
Quantitative RT-PCR (qRT-PCR)
Total RNA was prepared from each iPSC colony with a
PureLink RNA Micro Kit (Life Technologies). cDNA was
synthesized using a SuperScript III First-Strand Synthesis System
for RT-CR (Life Technologies) and applied for qRT-PCR with a
GoTaq qPCR Master mix (Promega) on a Realplex 2S system
(Eppendorf). Primers are listed in Table S2. The mRNA encoding
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used
for normalization.
DNA Microarray Analysis
RNA was prepared from WA09 ESCs, the dermal fibroblasts
from which all iPSCs in the microarray study were derived, two F-
iPSC clones, two L-iPSC clones and two LF-iPSC clones on day
100–140 with the PureLink RNA total RNA purification system
(Life Technologies). RNA quality was evaluated with a NanoDrop
8000 and an Agilent Bioanalyzer 2100. Biotin-labeled cRNA was
synthesized with a TotalPrep-96 RNA Amplification Kit (Life
Technologies/Applied Biosystems) following the manufacturer’s
instructions. cRNA was hybridized onto a HumanHT-12 v.4.0
Expression Beadchip (Illumina) following the Direct Hybridization
Gene Expression protocol. The Beadchips were then scanned
using an Illumina’s iScan instrument. Data were created using
Illumina’s GenomeStudio software and processed with Spotfire
DecisionSite for Functional Genomics software. DNA microarray
data have been deposited in the NCBI GEO database under the
accession number GSE37077.
Karyotyping
Colcemid-arrested iPSCs were treated with 0.75 M KCl
hypotonic solution, and fixed with methanol and acetic acid at a
3:1 ratio. Cell spreads were stained with Wright-Giemsa on glass
slides for G band analyses with the Applied Spectral Imaging
software.
Teratoma Formation
NOD/SCID mice were injected with 1–2610
6 iPSCs into the
hind limb muscle. Seven to eight weeks later, teratomas were
isolated, fixed with 10% formalin and embedded with paraffin.
Histological sections (5 mm thick) were prepared and stained with
haematoxylin and eosin.
Supporting Information
Table S1 Antibodies used for immunofluorescence
staining.
(DOC)
Table S2 Primers used for RT-PCR.
(DOC)
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